NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment
WASHINGTON, July 15, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention of vomiting induced by motion in 47 years, will sponsor the No. 47 entry in the NTT IndyCar...
WASHINGTON, July 15, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant), the first new prescription medication approved for prevention of vomiting induced by motion in 47 years, will sponsor the No. 47 entry in the NTT IndyCar...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.